Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 110.40K | 121.50K | 109.50K | 88.50K | 72.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.40K | 121.50K | 109.50K | 88.50K | 72.70K |
| Cost of Revenue | 42.10K | 34.90K | 38.80K | 33.60K | 37.50K |
| Gross Profit | 68.30K | 86.60K | 70.70K | 54.80K | 35.20K |
| SG&A Expenses | 418.20K | 265.50K | 255.40K | 274.30K | 330.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 460.20K | 300.40K | 294.20K | 308.00K | 368.00K |
| Operating Income | -349.80K | -178.90K | -184.80K | -219.50K | -295.30K |
| Income Before Tax | -1.40M | -230.90K | -260.70K | -367.10K | -426.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.40M | -230.90K | -260.70K | -367.10K | -426.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.40M | -230.90K | -260.70K | -367.10K | -426.90K |
| EBIT | -349.80K | -178.90K | -184.80K | -219.50K | -295.30K |
| EBITDA | -347.70K | -177.00K | -182.90K | -217.60K | -293.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.68B | 7.74B | 7.66B | 7.66B | 7.64B |
| Average Diluted Shares Outstanding | 7.68B | 7.74B | 7.66B | 7.66B | 7.64B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |